Skip to main content

Factors that have an Impact on Abbreviated New Drug Application (ANDA) Submissions



Increasing generic drug price competition by facilitating abbreviated new drug applications (ANDA) submission may help patients have access to affordable care. This study examined factors associated with first ANDA submission for the brand drug to be copied [the “reference listed drug” (RLD)].


This study used several data sources from 1/1/2011 to 12/31/2017, including FDA’s Approved Drug Products With Therapeutic Equivalence Evaluations (the Orange Book), internal ANDA submission data, FDA’s Product-Specific Guidances (PSGs), National Drug Code, and IQVIA National Sales Perspectives. Two Cox proportional hazard models were separately performed to determine factors associated with first ANDA submissions for groups of ANDAs for RLDs with “new chemical entity” (NCE) exclusivity that were submitted on the first lawfully permissible date NCE ANDAs, and non-NCE ANDA groups.


For NCE group, annual market sales were the only factor associated with increased likelihood of first ANDA submission. Specifically, adjusted hazard ratio (HR) for RLDs with annual sales > $250 million was nearly 5 times higher than those with annual sales < $10 million (HR 4.74; Confidence Interval [CI] 1.85–12.13) suggesting RLDs with higher sales are more likely to have ANDA submissions. For the non-NCE group, annual market sales (HR 2.40; CI 1.09–5.25, sales > $100–250 million compared with sales < $10 million) and PSG availability were associated with increased likelihood of first ANDA submission. Being an ANDA for a complex drug product was associated with decreased likelihood of submission for both NCE (HR 0.51; CI 0.26–0.99) and non-NCE groups (HR 0.62; CI 0.39–0.98).


Given the impact of regulatory-related factors, particularly PSG availability prior to ANDA submission, the findings provide opportunities to address high drug prices with specific FDA actions. Specifically, timely development of PSGs, including those for complex generics, and research prioritizing complex generics may facilitate ANDA submission; and thus, promote drug price competition.

This is a preview of subscription content, access via your institution.

Figure 1.
Figure 2.
Figure 3.
Figure 4.


  1. Office of the Assistant Secretary for Planning and Evaluation. U.S. Department of Health & Human Services. Observations on trends in prescription drug spending. 2016. Accessed 18 Sept 2018.

  2. IQVIA Institute for Human Data Science. Medicine Use and Spending in the U.S. A Review of 2017 and Outlook to 2022. Updated April 2018.

  3. Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA. 2016;316(8):858–71.

    Article  Google Scholar 

  4. Reiffen D, Ward MR. Generic drug industry dynamics. Rev Econ Stat. 2005;87(1):37–49.

    Article  Google Scholar 

  5. Association for Accessible Medicines. 2017 Generic drug access and savings in the U.S. Report. 2017. Accessed 02 Feb 2018.

  6. U.S. Department of Health and Human Services Food and Drug Administration. Estimating Cost Savings From Generic Drug Approvals in 2017. 2018. Accessed 20 Sept 2018.

  7. U.S. Food and Drug Administration. List of off-patent, off-exclusivity drugs without an approved generic. 2018. Accessed 27 May 2019.

  8. The Pew Charitable Trusts. FDA Approves More Generic Drugs, but Competition Still Lags. February 2019. Accessed 27 May 2019.

  9. U.S. Department of Health and Human Services. Food and Drug Administration. Electronic Code of Federal Regulations Title 21 Chapter I. Subchapter D. Part 314 Applications for FDA approval to market a new drug. Sec. 314.108 New drug product exclusivity.

  10. Toufanian M, Shimer M. Hatch-Waxman 101.

  11. Renu L. Patents and Exclusivity.

  12. U.S. Food and Drug Administration. Frequently Asked Questions on Patents and Exclusivity.

  13. Olson LM, Wendling BW. Estimating the Effect of Entry on Generic Drug Prices Using Hatch-Waxman Exclusivity 2013.

  14. Wang B, Liu J, Kesselheim AS. Variations in time of market exclusivity among top-selling prescription drugs in the United States. JAMA Intern Med. 2015;175(4):635–7.

    Article  Google Scholar 

  15. Appelt S. Authorized generic entry prior to patent expiry: reassessing incentives for independent generic entry. Rev Econ Stat. 2015;97(3):654–66.

    Article  Google Scholar 

  16. Bae JP. Drug patent expirations and the speed of generic entry. Health Serv Res. 1997;32(1):87–101.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Morton FM. Entry decisions in the generic pharmaceutical industry. Rand J Econ. 1999;30(3):421–40.

    Article  CAS  Google Scholar 

  18. Hu M, Babiskin A, Wittayanukorn S, et al. Predictive analysis of first Abbreviated New Drug Application submission for new chemical entities based on machine learning methodology. Clin Pharmacol Ther. 2019;106(1):174–81.

    Article  Google Scholar 

  19. Daizadeh I. Investigating rates of food and drug administration approvals and guidances in drug development: a structural breakpoint/cointegration timeseries analysis. Ther Innov Regul Sci. 2020.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Testimony of Janet Woodcock MD. Implementation of the Generic Drug User Fee Amendments of 2012 (GDUFA), Testimony before the Senate Committee on Health, Education, Labor, and Pensions, January 28, 2016. Accessed 29 May 2018.

  21. U.S. Department of Health and Human Services. Food and Drug Administration. Statement from FDA Commissioner Scott Gottlieb, M.D. on new steps to facilitate efficient generic drug review to enhance competition, promote access and lower drug prices. 2018. Accessed 8 Sept 2019.

  22. U.S. Food and Drug Administration. Product-Specific Guidances for Generic Drug Development. Updated March 2018.

  23. Woo J, Luan JJ, Li Z, Grosser S, Peters J, Chazin H. Abbreviated new drug applications: generic drug user fee amendments act analysis of application quality metrics. Ther Innov Regul Sci. 2018;53(5):696–700.

  24. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Accessed March 2018.

  25. The National Drug Code (NDC) Directory. Accessed March 2018.

  26. Approved Risk Evaluation and Mitigation Strategies (REMS). Accessed March 2018.

  27. U.S. Food and Drug Administration. GDUFA Reauthorization Performance Goals and Program Enhancements Fiscal Years 2018–2022. Updated 9 May 2018. Accessed 26 Jan 2020.

  28. IQVIA National Sales Perspectives, IQVIA Institute, Calendar Year 2011–2017.

  29. Grabowski H, Long G, Mortimer R. Recent trends in brand-name and generic drug competition. J Med Econ. 2014;17(3):207–14.

    Article  Google Scholar 

  30. Grabowski H, Long G, Mortimer R, Boyo A. Updated trends in US brand-name and generic drug competition. J Med Econ. 2016;19(9):836–44.

    Article  Google Scholar 

  31. Lionberger RA. FDA critical path initiatives: opportunities for generic drug development. AAPS J. 2008;10(1):103–9.

    Article  Google Scholar 

  32. Saha A, Grabowski H, Birnbaum H, Greenberg P, Bizan O. Generic competition in the US pharmaceutical industry. Int J Econ Bus. 2006;13(1):15–38.

    Article  Google Scholar 

  33. Smith K, Gleklen J. CPI Antitrust chronicle generic drugmakers will challenge patents even when they have a 97% chance of losing: the FTC Report that K-Dur Ignored. Accessed 6 June 2018.

  34. U.S. Food and Drug Administration. CDER Conversation: patents and exclusivities for generic drug products. September 2017. Accessed 4 May 2019.

  35. U.S. Food and Drug Administration. Manual of policies and procedures: prioritization of the review of original ANDAs, Amendments, and Supplements. 2017. Accessed 26 Jan 2020.

Download references


No financial support of the research, authorship, and/or publication of this article was declared.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Andrew Babiskin PhD.

Ethics declarations

Conflict of interest

No potential conflicts were declared.

Additional information

Disclaimer: The views expressed in this article are those of the authors and not necessarily those of the Food and Drug Administration (FDA).

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 343 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wittayanukorn, S., Rosenberg, M., Schick, A. et al. Factors that have an Impact on Abbreviated New Drug Application (ANDA) Submissions. Ther Innov Regul Sci 54, 1372–1381 (2020).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


  • Generic drugs
  • Drug submission
  • Bioequivalence
  • New chemical entity